Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI 0457

Next Previous
Drug Profile

MEDI 0457

Alternative Names: INO-3112; INO-9012/VGX-3100; MEDI-0457; VGX-3100 plus IL-12; VGX-3100/INO-9012

Latest Information Update: 17 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Pennsylvania
  • Developer AstraZeneca; Inovio Pharmaceuticals; University of Pennsylvania; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies; Papillomavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer; Head and neck cancer
  • Phase I/II Cervical cancer
  • No development reported Oropharyngeal cancer

Most Recent Events

  • 31 Dec 2024 Inovio Pharmaceuticals gains alignment with the US FDA on the planned phase phase III trial design in Squamous cell cancer and received initial feedback from European regulatory authorities on proposed trial design, before December 2024
  • 13 May 2024 Inovio Pharmaceuticals plans a phase III trial for Oropharyngeal squamous cell carcinoma (OPSCC) (Combination therapy) in Europe and North America
  • 01 Mar 2023 Efficacy data from a phase Ib/IIa trial in Head and neck cancer released by Inovio Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top